Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670010 | 0.82 | KMT2A (0.44) | SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL32669822 | 0.82 | LTB4R (0.41) | ALDH1A1KDM4E | |
| SCHEMBL32670068 | 0.82 | KDM4E (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL32669930 | 0.81 | RAB9A (0.38) | SMN1; SMN2RAB9AMAPTMEN1KMT2A | |
| SCHEMBL32669759 | 0.79 | PORCN (0.36) | NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL32669969 | 0.78 | FTO (0.50) | SMN1; SMN2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL32669571 | 0.77 | SLC22A12 (0.36) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL32669598 | 0.76 | COMT (0.32) | ALDH1A1KDM4E | |
| SCHEMBL32669964 | 0.75 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL32669810 | 0.75 | EGFR (0.34) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | SMN1; SMN2 2140/4885NPC1 40/4885RAB9A 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.